Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.50.

A number of brokerages have commented on CLDX. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, August 9th. BidaskClub downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The company’s revenue for the quarter was up 175.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.32) EPS.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/02/celldex-therapeutics-inc-cldx-given-consensus-recommendation-of-hold-by-analysts.html.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after purchasing an additional 708,095 shares during the period. Meditor Group Ltd lifted its position in shares of Celldex Therapeutics by 8.8% in the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares during the period. State Street Corp lifted its position in shares of Celldex Therapeutics by 4.7% in the 1st quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after purchasing an additional 202,375 shares during the period. Northern Trust Corp lifted its position in shares of Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Celldex Therapeutics by 42.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after purchasing an additional 508,217 shares during the period. 57.07% of the stock is owned by hedge funds and other institutional investors.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.